Mumbai: Lupin Limited (Lupin) has revealed that it received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Mandideep Unit-2 manufacturing facility.
This report comes after the recent inspection of the facility that took place from August 7 to August 11, 2023. The inspection concluded with the facility being classified as “No Action Indicated” (NAI).
“We are pleased to receive the EIR with a satisfactory inspection status from the U.S. FDA for the recent inspection of our Mandideep Unit-2 facility. This accomplishment is in line with our continued focus and commitment to becoming best-in-class in quality and compliance, and enables us to continue delivering quality affordable healthcare solutions globally,” said Nilesh Gupta, Managing Director, Lupin.
